Alternating carboplatin and doxorubicin as adjunctive chemotherapy to amputation or limb-sparing surgery in the treatment of appendicular osteosarcoma in dogs.
Thirty-two dogs with appendicular osteosarcoma treated by amputation or limb sparing had adjuvant chemotherapy of alternating doses of carboplatin (300 mg/m2 IV) and doxorubicin (30 mg/m2 IV) every 21 days for a total of 3 cycles. Efficacy, toxicity, and previously identified prognostic factors for osteosarcoma were evaluated. The median progression free survival was 227 days (range 180-274), and the median overall survival was 320 days (range 153-487). The 1-year survival rate was 48%, and the 2-year survival rate was 18%. Age, sex, surgical procedure, and alkaline phosphatase activity above the reference ranges were not prognostic for survival. There was minimal toxicity associated with the chemotherapy. This protocol could be useful for the adjuvant treatment of appendicular osteosarcoma of dogs.
Kent
Michael S
MS
Department of Surgical and Radiological Sciences, University of California, Davis, CA 95616-8745, USA. mskent@ucdavis.edu
Strom
Adam
A
London
Cheryl A
CA
Seguin
Bernard
B
D000671:Amputation, Surgical / Q000662:veterinary; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000662:veterinary*; D002140:California / Q000453:epidemiology; D016190:Carboplatin / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D004283:Dog Diseases / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D004285:Dogs; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005121:Extremities; D005260:Female; D007262:Infusions, Intravenous / Q000662:veterinary; D008297:Male; D012516:Osteosarcoma / Q000188:drug therapy / Q000601:surgery / Q000662:veterinary*; D011996:Records / Q000662:veterinary; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
D004317:Doxorubicin; D016190:Carboplatin